Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
MODIFIED ADENOVIRUS AND MEDICINE COMPRISING SAME
Document Type and Number:
WIPO Patent Application WO/2020/189749
Kind Code:
A1
Abstract:
[Problem] The purpose of the present invention is to provide a modified adenovirus having a cytocidal activity on a target cell and high safety. [Solution] The present invention pertains to: a modified adenovirus which comprises an E1A gene, an enhancer sequence having a function of enhancing the expression of the E1A gene, and an AU-rich element introduced into the 3'-untranslated region of a viral gene, which is essentially required for the self-propagation thereof, or a position adjacent to the 3'-untranslated region, or a modified adenovirus which comprises an E1A gene and an enhancer sequence having a function of enhancing the expression of the E1A gene and cannot express normal E4orf6 protein, wherein the distance between the 5'-terminus of the E1A gene and the terminus of the enhancer sequence is 1500-4500 bp; and a medicine comprising the same.

Inventors:
HIGASHINO FUMIHIRO (JP)
Application Number:
PCT/JP2020/012196
Publication Date:
September 24, 2020
Filing Date:
March 19, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV HOKKAIDO NAT UNIV CORP (JP)
International Classes:
A61K48/00; A61K35/761; A61P29/00; A61P35/00; C12N7/01; C12N15/34
Foreign References:
JP2016160249A2016-09-05
JP2016160249A2016-09-05
Other References:
ELOIT M. ET AL.: "Isogenic adenoviruses type 5 expressing or not expressing the E1A gene : efficiency as virus vectors in the vaccination of permissive and non-permissive species", JOURNAL OF GENERAL VIROLOGY, vol. 76, 1995, pages 1583 - 1589, XP002028963
HEARING P. ET AL.: "The adenovirus type 5 E1A enhancer contains two functionally distinct domains: one is specific for E1A and the other modulates all early units in cis", CELL, vol. 45, 1986, pages 229 - 236, XP024244018, DOI: 10.1016/0092-8674(86)90387-9
HALBERT D. N. ET AL.: "Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff", JOURNAL OF VIROLOGY, vol. 56, no. 1, 1985, pages 250 - 257, XP001000467
MIKAWA YOHEI, TOWFIK ALAM MOHAMMAD, HOSSAIN ELORA, YANAGAWA-MATSUDA AYA, KITAMURA TETSUYA, YASUDA MOTOAKI, HABIBA UMMA, AHMED ISHR: "Conditionally replicative adenovirus controlled by the stabilization system of AU -rich elements containing mRNA", CANCERS, vol. 12, no. 5, 1205, 11 May 2020 (2020-05-11), pages 1 - 13, XP055851593, DOI: 10.3390/cancers12051205
BISCHOFF ET AL., SCIENCE, vol. 274, 1996, pages 373 - 376
HIGASHINO ET AL., J. CELL BIOL., vol. 170, 2005, pages 15 - 20
HALBERT ET AL., J. VIROLOGY, vol. 56, 1985, pages 250 - 257
LOPEZ ET AL., ONCOGENE, vol. 22, 2003, pages 7146 - 7154
THIELE ET AL., EXP. CELL RES., vol. 312, no. 12, 2006
LOGAN ET AL., CANCER CELLS, vol. 2, 1984, pages 527 - 532
See also references of EP 3943113A4
Attorney, Agent or Firm:
IP-ASSIST PATENT OFFICE (JP)
Download PDF: